U.S. Markets closed

Looking At Lee's Pharmaceutical Holdings Limited (HKG:950) From All Angles

Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

I've been keeping an eye on Lee's Pharmaceutical Holdings Limited (HKG:950) because I'm attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe 950 has a lot to offer. Basically, it is a financially-robust , dividend-paying company with a great history of performance. Below, I've touched on some key aspects you should know on a high level. For those interested in understanding where the figures come from and want to see the analysis, read the full report on Lee's Pharmaceutical Holdings here.

Flawless balance sheet established dividend payer

950 delivered a bottom-line expansion of 54% in the prior year, with its most recent earnings level surpassing its average level over the last five years. In addition to beating its historical values, 950 also outperformed its industry, which delivered a growth of 19%. This is an optimistic signal for the future. 950's strong financial health means that all of its upcoming liability payments are able to be met by its current cash and short-term investment holdings. This suggests prudent control over cash and cost by management, which is a key determinant of the company’s health. 950 appears to have made good use of debt, producing operating cash levels of 2.45x total debt in the prior year. This is a strong indication that debt is reasonably met with cash generated.

SEHK:950 Income Statement, July 1st 2019

For those seeking income streams from their portfolio, 950 is a robust dividend payer as well. Over the past decade, the company has consistently increased its dividend payout, reaching a yield of 2.2%.

SEHK:950 Historical Dividend Yield, July 1st 2019

Next Steps:

For Lee's Pharmaceutical Holdings, there are three key aspects you should further research:

  1. Future Outlook: What are well-informed industry analysts predicting for 950’s future growth? Take a look at our free research report of analyst consensus for 950’s outlook.
  2. Valuation: What is 950 worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether 950 is currently mispriced by the market.
  3. Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of 950? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.